In March 2026, FDA issued a draft guidance, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, intended to assist human and animal drug manufacturers in responding to observations issued at the close of a CGMP inspection. The draft guidance addresses how establishments that receive a Form 483 should respond and reiterates that a Form 483 is not a final Agency compliance determination. At the same time, FDA makes clear that a written response can be an important part of the Agency's evaluation of whether additional action is warranted. FDA solicited comments on the draft guidance through May 8, 2026.
What does the guidance recommend?
The overarching recommendation expressed by the draft guidance is that a 483 response should be timely, comprehensive, and easy for FDA to evaluate. FDA recommends submitting one organized written response within 15 business days, rather than piecemeal submissions, and suggests that the response should at least include:
- A table of contents
- The identity of the inspected establishment, including site name, address, and FDA Establishment Identifier (FEI)
- A copy of the issued Form 483
- The identities of the response preparer and signatory
- Any letters of authorization for consultants or outside counsel
- Relevant investigation plans, reports, and supporting materials
- A discussion of each Form 483 observation, or grouped observations, and the associated remediation activities
- An executive summary of remediation activities and
- Attachments related to the observations, such as documents, data, photographs, videos, diagrams, or other evidence
The response should be signed by a member of executive management or another person with authority to allocate resources and implement commitments. For complex observations that cannot be fully remediated within 15 business days, the response should still provide a CAPA plan, interim controls, and a realistic timetable for completion and follow-up reports.
Substantively, FDA is looking for more than assurances that the company will fix the problem. The draft guidance emphasizes patient- and product-focused risk assessments, including consideration of distributed product and inventory still within expiry; investigations that identify scope, root cause, affected products or lots, systemic issues, and related trends; and CAPAs that are realistic, measurable, achievable, implemented in all affected areas, and verified for effectiveness. FDA also encourages companies to seek clarification during the inspection and, where a scientific or technical disagreement remains, to explain the contested facts with supporting data and a regulatory rationale. In practice, a strong 483 response should tell a coherent story that explains what happened, why it happened, how far the issue extends, what immediate controls are in place, what permanent fixes will be implemented, and how the company will know those fixes worked. The guidance emphasizes, however, that partially implemented or promised corrective actions do not preclude FDA from taking regulatory action at any time.
What about other FDA-regulated sectors?
Although the draft guidance is directed to drug CGMP inspections, Form 483 observations are not unique to the drug sector. FDA-regulated companies in the food, dietary supplements, medical devices, cosmetics, and other product areas may also receive Form 483s following inspections. FDA has not issued a comparable sector-specific guidance for all such sectors. We are aware that device establishments have separate guidance on requesting nonbinding feedback after certain device inspections, but companies in other sectors often must work from more general FDA inspection principles and sector-specific regulatory requirements. In that vacuum, the draft Form 483 response guidance for drugs may offer useful principles for businesses in other FDA-regulated sectors: respond promptly; organize the response so FDA can evaluate it; assess product and public-health risk; investigate scope and root cause; make credible CAPA commitments; and document effectiveness.
What's next?
With the comment period closed, FDA may revise the draft before finalizing it, but companies need not wait to use it as a benchmark. For any regulated company that receives a Form 483, the first few days after the inspection closeout meeting are critical. Coordinating quality, operations, regulatory, legal, and executive leadership early can help ensure the response is not merely a promise to remediate, but a credible, evidence-based plan tailored to the observations, the product risk, and the applicable regulatory framework. Companies that receive a Form 483 should consider seeking experienced FDA legal support to help assess the observations, develop the response strategy, and manage follow-through. Venable's Food and Drug Law team is here to help; please contact a member of the team with any questions.